Effects of GM-CSF Treatment in Prostate Cancer Patients
Author Information
Author(s): Amato Robert J., Hernandez-McClain Joan
Primary Institution: The Methodist Hospital Research Institute
Hypothesis
Does chronic GM-CSF dosing affect PSA levels in men with hormone-refractory or hormone-naïve prostate cancer?
Conclusion
GM-CSF treatment may be beneficial for hormone-naïve patients but not for hormone-refractory patients.
Supporting Evidence
- Two hormone-naïve patients had progressive disease after 1 and 4 treatment cycles.
- Seven hormone-naïve patients had PSA declines ranging from 7% to 42%.
- Three hormone-refractory patients had a best PSA response of 3% to 32% decline.
Takeaway
This study looked at a treatment for prostate cancer using a substance called GM-CSF, and it found that it helped some patients who hadn't had hormone treatment before.
Methodology
Patients received GM-CSF injections three times a week for 12 weeks, and PSA levels were measured every six weeks.
Limitations
The trial was closed early due to insufficient responses in hormone-refractory patients.
Participant Demographics
Included 6 hormone-refractory and 10 hormone-naïve patients, median ages 76 and 64 years respectively.
Want to read the original?
Access the complete publication on the publisher's website